Investment Office Monthly Fund Digest (October 2023)

In our October issue of the Endowus fund digest, we introduce 4 new funds covering a variety of sectors including Biotechnology, Shariah and ESG — across equities and fixed income offerings. 

While Biotechnology has been a perennial favourite, Shariah funds have always attracted investors who are looking for socially responsible investment options due to their guidelines and transparency requirements and now, combined with a portfolio of high-conviction technology companies based off the popular Franklin Technology Fund.

Read more below.

Biotechnology Equities

Janus Henderson Horizon Biotechnology Fund

‍ISIN: LU1988887292 (SGD, Cash/SRS, Acc), LU1897414303 (USD, Cash, Acc)

This Fund offers a dynamic and diversified approach to biotechnology investments, spanning 50-80 companies across all sizes and stages. It stands out as a pure biotech fund, dedicated exclusively to biotech and specialised pharmaceuticals with a focus on smaller-sized developmental stage firms. 

Notably, the Fund has demonstrated robust outperformance against its benchmark and peers since its inception in December 2018, showcasing a favourable track record in a high-growth, high-volatility sub-sector where stock prices can fluctuate significantly based on clinical trial outcomes and regulatory events. 

The Fund is led by industry veteran Andy Acker, with 27 years of experience, who is supported by a stable team of two Co-PMs, and offers a reliable approach to biotech investing.

<medium-btn-link>Find out more<medium-btn-link>

Shariah Equities

Franklin Shariah Technology Fund

ISIN: LU2458330169 (SGD, Cash/SRS, Acc), LU2432581036 (USD, Cash, Acc)

This Fund offers a dynamic and diversified approach to biotechnology investments, spanning 50-80 companies across all sizes and stages. It stands out as a pure biotech fund, dedicated exclusively to biotech and specialised pharmaceuticals with a focus on smaller-sized developmental stage firms. 

Notably, the Fund has demonstrated robust outperformance against its benchmark and peers since its inception in December 2018, showcasing a favourable track record in a high-growth, high-volatility sub-sector where stock prices can fluctuate significantly based on clinical trial outcomes and regulatory events. 

The Fund is led by industry veteran Andy Acker, with 27 years of experience, who is supported by a stable team of two Co-PMs, and offers a reliable approach to biotech investing.

<medium-btn-link>Find out more<medium-btn-link>

Sukuk (Shariah Fixed Income)

Franklin Global Sukuk Fund

ISIN: LU0923116197 (SGD, Cash/SRS, Dist)

This Fund stands out as one of the very few retail Sukuk options available in Singapore, making it a compelling choice especially for Muslim investors seeking alternatives to conventional interest-bearing fixed income. The Fund received a fatwa in September 2011 and comes with independent endorsement from the Amanie International Shariah Supervisory Board, further enhancing its credibility.

Managed from Dubai by CIO Mohieddine Kronfo and Portfolio Manager Sharif Eid, the fund benefits From a team of six research analysts and leverages the expertise of over 130 dedicated fixed income investment professionals at Franklin Templeton. With a commitment to Shariah law, the team applies its collective knowledge to manage the sukuk portfolio.

Since inception, the fund has consistently outperformed the majority of its peers, delivering Shariah-compliant performance closely aligned with the broader fixed income asset class.

<medium-btn-link>Find out more<medium-btn-link>

ESG Fixed Income

Allspring Climate Transition Global Investment Grade Credit Fund 

ISIN:LU2667752377 (SGD, Cash/SRS, Acc), LU1826612522 (USD, Cash, Acc)

Strategically designed to offer exposure to the vast global investment-grade corporate bond universe, the Fund’s standout feature is its clear climate transition objective – it aims for net-zero carbon emissions by 2050 while achieving substantial immediate reductions in carbon intensity. The Fund is led by portfolio managers Henrietta Pacquement and Scott Smith with an average experience of over 25 years, and is supported by a sizable team of over 80 global fixed income analysts.

The Fund incorporates a well-thought-out climate transition framework deeply integrated into its fundamental analysis, with a focus on identifying transition outperformers. Unlike some of its ESG peers, it actively encourages and rewards climate transition leaders, and is not limited to investments in low carbon emitters.

<medium-btn-link>Find out more<medium-btn-link>

Customise your portfolio in minutes with Fund Smart

Whether you’re looking to invest your cash, CPF, or SRS, there’s something for everyone at Endowus. Want to know more about the funds available on our Fund Smart platform? Refer to our investment funds list here for a quick overview in a single glance. 

We also recently gave the Fund Smart platform a massive upgrade — including wider currency options, new dividend payout options, and an improved experience for verified accredited investors. These give you more flexibility and information in selecting your own funds and building your own portfolios. What’s more, you can transfer your funds from other banks or platforms into Endowus, saving you up to 50% or more on your fees.

Customise your ideal investment portfolio in minutes with Fund Smart. The Endowus Fee for Single Fund Goals via Fund Smart (Cash, CPF, and SRS) is 0.3% p.a., reinforcing our commitment to reduce the cost of investing. This pricing means that more than 95% of the funds are now cheaper on Endowus than on any other fund platform, bank, private bank, financial advisor, or broker in Singapore. 

Not sure how to invest with Fund Smart? Find out everything you need to know in our FAQs.

<divider><divider>

*Annualised returns are calculated based on the returns of the target share class, and the oldest share class of the fund where the target share class is younger than three years. Three-year returns are based on the period from October 2020 to September 2023 unless otherwise stated. Returns are translated into SGD (except for non-SGD funds) and are net of fund-level fees. 

**Where a fund or portfolio has both SGD and USD share classes, the fees of the SGD share class are shown. Total portfolio and fund-level fees include fund total fund-level fees.

***Endowus does not charge a preliminary sales charge or any other additional fees, other than the all-in Endowus Fee.